Ching-Feng Weng

Prof. Ching-Feng Weng

Department of Life Science and Institute of Biotechnology, National Dong Hwa University, Hualien, Taiwan
+1
orcid

Research Focus & Metrics

Academic Career Length

37Years (1990-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in British Journal of Pharmacology
Verified
Journal Article
Open access
PDF file
SLShian-Ren Lin
Shian-Ren Lin
CCChia‐Hsiang Chang
Chia‐Hsiang Chang
CHChe‐Fang Hsu
Che‐Fang Hsu
MTMay‐Jwan Tsai
May‐Jwan Tsai
HCHenrich Cheng
Henrich Cheng
Ching-Feng WengChing-Feng Weng
Ching-Feng Weng
Traditional chemotherapy is being considered due to hindrances caused by systemic toxicity. Currently, the administration of multiple chemotherapeutic drugs with different biochemical/molecular targets, known as combination chemotherapy, has attained numerous benefits like efficacy enhancement and amelioration of adverse effects that has been broadly applied to various cancer types. Additionally, seeking natural‐based alternatives with less toxicity has become more important. Experimental evidence suggests that herbal extracts such as Solanum nigrum and Claviceps purpurea and isolated herbal compounds (e.g., curcumin, resveratrol, and matairesinol) combined with antitumoral drugs have the potential to attenuate resistance against cancer therapy and to exert chemoprotective actions. Plant products are not free of risks: Herb adverse effects, including herb–drug interactions, should be carefully considered.Linked Articles: This article is part of a themed section on The Pharmacology of Nutraceuticals. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.6/issuetoc

1 September 2021 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
YFYaw-Syan Fu
Yaw-Syan Fu
TCTing-Hsu Chen
Ting-Hsu Chen
LWLebin Weng
Lebin Weng
LHLiyue Huang
Liyue Huang
DLDong Lai
Dong Lai
Ching-Feng WengChing-Feng Weng
Ching-Feng Weng
Curcumin, isolated from Curcuma longa L., is a fat-soluble natural compound that can be obtained from ginger plant tuber roots, which accumulative evidences have demonstrated that it can resist viral and microbial infection and has anti-tumor, reduction of blood lipid and blood glucose, antioxidant and removal of free radicals, and is active against numerous disorders various chronic diseases including cardiovascular, pulmonary, neurological and autoimmune diseases. In this article is highlighted the recent evidence of curcuminoids applied in sevral aspects of medical problem particular in COVID-19 pandemics. We have searched several literature databases including MEDLINE (PubMed), EMBASE, the Web of Science, Cochrane Library, Google Scholar, and the ClinicalTrials.gov website via using curcumin and medicinal properties as a keyword. All studies published from the time when the database was established to May 2021 was retrieved. This review article summarizes the growing confirmation for the mechanisms related to curcumin's physiological and pharmacological effects with related target proteins interaction via molecular docking. The purpose is to provide deeper insight and understandings of curcumin's medicinal value in the discovery and development of new drugs. Curcumin could be used in the prevention or therapy of cardiovascular disease, respiratory diseases, cancer, neurodegeneration, infection, and inflammation based on cellular biochemical, physiological regulation, infection suppression and immunomodulation.

14 December 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
JRJirawat Riyaphan
Jirawat Riyaphan
DPDinh-Chuong Pham
Dinh-Chuong Pham
MLMax K. Leong
Max K. Leong
Ching-Feng WengChing-Feng Weng
Ching-Feng Weng
Type-II diabetes mellitus (T2DM) results from a combination of genetic and lifestyle factors, and the prevalence of T2DM is increasing worldwide. Clinically, both α-glucosidase and α-amylase enzymes inhibitors can suppress peaks of postprandial glucose with surplus adverse effects, leading to efforts devoted to urgently seeking new anti-diabetes drugs from natural sources for delayed starch digestion. This review attempts to explore 10 families e.g., Bignoniaceae, Ericaceae, Dryopteridaceae, Campanulaceae, Geraniaceae, Euphorbiaceae, Rubiaceae, Acanthaceae, Rutaceae, and Moraceae as medicinal plants, and folk and herb medicines for lowering blood glucose level, or alternative anti-diabetic natural products. Many natural products have been studied in silico, in vitro, and in vivo assays to restrain hyperglycemia. In addition, natural products, and particularly polyphenols, possess diverse structures for exploring them as inhibitors of α-glucosidase and α-amylase. Interestingly, an in silico discovery approach using natural compounds via virtual screening could directly target α-glucosidase and α-amylase enzymes through Monte Carto molecular modeling. Autodock, MOE-Dock, Biovia Discovery Studio, PyMOL, and Accelrys have been used to discover new candidates as inhibitors or activators. While docking score, binding energy (Kcal/mol), the number of hydrogen bonds, or interactions with critical amino acid residues have been taken into concerning the reliability of software for validation of enzymatic analysis, in vitro cell assay and in vivo animal tests are required to obtain leads, hits, and candidates in drug discovery and development.

7 July 2015 in BioFactors
Verified
Journal Article
Closed access
PDF file
CJChien‐Hung Jhong
Chien‐Hung Jhong
JRJirawat Riyaphan
Jirawat Riyaphan
SLShih‐Hung Lin
Shih‐Hung Lin
YCYi‐Chen Chia
Yi‐Chen Chia
Ching-Feng WengChing-Feng Weng
Ching-Feng Weng

27 September 2018 in Molecules
Verified
Journal Article
Open access
PDF file
BVBharath Kumar Velmurugan
Bharath Kumar Velmurugan
Rathinasamy BaskaranRathinasamy Baskaran
Rathinasamy Baskaran
BLBharathi Priya Lohanathan
Bharathi Priya Lohanathan
TVThiyagarajan Varadharajan
Thiyagarajan Varadharajan
Ching-Feng WengChing-Feng Weng
Ching-Feng Weng
Neurodegenerative diseases are normally distinguished as disorders with loss of neurons. Various compounds are being tested to treat neurodegenerative diseases (NDs) but they possess solitary symptomatic advantages with numerous side effects. Accumulative studies have been conducted to validate the benefit of phytochemicals to treat neurodegenerative diseases including Alzheimer’s disease (AD) and Parkinson’s disease (PD). In this present review we explored the potential efficacy of phytochemicals such as epigallocatechin-3-galate, berberin, curcumin, resveratrol, quercetin and limonoids against the most common NDs, including Alzheimer’s disease (AD) and Parkinson’s disease (PD). The beneficial potentials of these phytochemicals have been demonstrated by evidence-based but more extensive investigation needs to be conducted for reducing the progression of AD and PD.

Verified
Journal Article
Open access
PDF file
SLShian-Ren Lin
Shian-Ren Lin
YFYaw Syan Fu
Yaw Syan Fu
MTMay-jywan Tsai
May-jywan Tsai
HCHenrich Cheng
Henrich Cheng
Ching-Feng WengChing-Feng Weng
Ching-Feng Weng
Accumulated evidence indicates that autophagy is a response of cancer cells to various anti-cancer therapies. Autophagy is designated as programmed cell death type II, and is characterized by the formation of autophagic vacuoles in the cytoplasm. Numerous herbs, including Chinese herbs, have been applied to cancer treatments as complementary and alternative medicines, supplements, or nutraceuticals to dampen the side or adverse effects of chemotherapy drugs. Moreover, the tumor suppressive actions of herbs and natural products induced autophagy that may lead to cell senescence, increase apoptosis-independent cell death or complement apoptotic processes. Hereby, the underlying mechanisms of natural autophagy inducers are cautiously reviewed in this article. Additionally, three natural compounds—curcumin, 16-hydroxycleroda-3,13-dien-15,16-olide, and prodigiosin—are presented as candidates for autophagy inducers that can trigger cell death in a supplement or alternative medicine for cancer therapy. Despite recent advancements in therapeutic drugs or agents of natural products in several cancers, it warrants further investigation in preclinical and clinical studies.